Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of BLU-945 in acquired resistance EGFR-mutant non-small cell lung cancer
CTR20221771Phase 2Suspended
- Sponsor
- Blueprint Medicines
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tigozertinib in non-small cell lung cancer (NSCLC), sponsored by Blueprint Medicines. Started Aug 2022; status: suspended.
02
Drugs
tigozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20221771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221771.